BMJ  2007;334:1022 (19 May), doi:10.1136/bmj.39216.489780.DB

News

FDA calls for warnings on anaemia drugs amid reports of incentives to doctors

New York

The first 150 words of the full text of this article appear below.

The committee of the US Food and Drug Administration (FDA) that advises on oncology drugs last week recommended new warnings on erythropoiesis stimulating drugs that are given to patients undergoing chemotherapy to counteract anaemia. Patients undergoing dialysis are also often given the drugs.

The committee said that such synthetic erythropoietins (also called epoetins or "epo drugs") were associated with an increased risk of cardiovascular events and possibly of progression of cancer. It unanimously recommended new clinical trials.

The FDA committee's recommendations came only days after the New York Times published a story on its front page headlined "Doctors reaping millions for use of anemia drugs" (www.nytimes.com, 9 May) and the Wall Street Journal reported how Johnson & Johnson promoted epoetin alfa (www.wsj.com, 10 May "Suit details how J&J pushed sales of Procrit").

In March the FDA called for a review of two drugs made by Amgen, . . . [Full text of this article]

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

US agency limits payments for anaemia drugs

Jeanne Lenzer
BMJ 2007 334: 1079. [Extract] [Full Text]

Too much of a good thing

Alison Tonks
BMJ 2007 334: 978-980. [Extract] [Full Text] [PDF]

Safety of anaemia drug erythropoietin is to be reviewed

Jeanne Lenzer
BMJ 2007 334: 495. [Extract] [Full Text] [PDF]

Online poll

Find out more >>